24-Mar-2026
TipRanks (Mon, 23-Mar 7:40 PM ET)
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Business Wire (Thu, 19-Feb 4:01 PM ET)
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Business Wire (Thu, 12-Feb 4:30 PM ET)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Wed, 11-Feb 5:00 PM ET)
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
Business Wire (Wed, 4-Feb 4:30 PM ET)
Globe Newswire (Fri, 30-Jan 8:50 PM ET)
PRNewswire (Wed, 28-Jan 7:10 AM ET)
TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses
Globe Newswire (Tue, 27-Jan 7:54 AM ET)
Market Chameleon (Fri, 16-Jan 6:22 AM ET)
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Travere Therapeutics trades on the NASDAQ stock market under the symbol TVTX.
As of March 24, 2026, TVTX stock price declined to $26.79 with 722,618 million shares trading.
TVTX has a beta of 1.62, meaning it tends to be more sensitive to market movements. TVTX has a correlation of 0.16 to the broad based SPY ETF.
TVTX has a market cap of $2.47 billion. This is considered a Mid Cap stock.
Last quarter Travere Therapeutics reported $130 million in Revenue and $.37 earnings per share. This fell short of revenue expectation by $-16 million and exceeded earnings estimates by $.13.
In the last 3 years, TVTX traded as high as $42.13 and as low as $5.12.
The top ETF exchange traded funds that TVTX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.
TVTX has outperformed the market in the last year with a return of +30.5%, while the SPY ETF gained +17.1%. However, in the most recent history, TVTX shares have underperformed the stock market with its stock returning -24.2% in the last 3 month period and -7.6% for the last 2 week period, while SPY has returned -4.8% and -3.4%, respectively.
TVTX support price is $26.92 and resistance is $28.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TVTX shares will trade within this expected range on the day.